31 Dec 2021
December brings more than the usual to celebrate for MICA Biosystems
'Tis the season the for revelry and joy in more than one way for us here at MICA Biosystems. Thanks to the hard work of our team during Q4 of this year, we have managed to secure a further investment of £200k from Innovate UK. This influx of capital is in addition to our currently-open Bridge-Series investment round.
We'll be using this capital to kick-start our work with The Royal Orthopaedic Hospital NHS Foundation Trust to begin work with their clinic, and to pave the way to starting our Clinical Trials. In addition to this, we'll be investing in further widening our IP portfolio and increasing our team. We're also making our first approach to the Medicines and Healthcare products Regulatory Agency (MHRA) in the new year and preparing for an approach to the European Medicines Agency to outline our first-in-man plans.
2021 has been an incredible and exciting year for MICA Biosystems with the end of Q4 proving not to deviate from the continued upward trajectory of the company over the last 12 months. The commencement of our work with The Royal Orthopaedic Hospital NHS Foundation Trust at the beginning of 2022 opens up a new chapter in our continued development, a chapter which brings us one step closer to our aim of revolutionising regenerative healthcare.